Any guesses on $amount from the JV revenue anticipated will end up as profit?
I assume the JV will be a 50/50 split? My bad just saw 49/51
What are the odds of getting FDA approval in China and anticipated timeframe to get?
Based on current CMP figures of NPAT guidance of $5m on $40m rev = 12.5%
So on $66m AUD p.a could be $8m NPAT/2 (JV) ∼$4m NPAT over at CMP?
So just 1.5 x revenue and possibly doubled NPAT
Puts it at say $10m NPAT p.a, with 100m shares could well see $200m+ MCAP once implemented and factual.
Plenty of growth here it seems, hmmm on the watchlist, might even buy a few on the dips.
CMP Price at posting:
68.5¢ Sentiment: Buy Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)